Novel bispecific T-cell engager molecule shows promise in r/r multiple myeloma
Novel bispecific T-cell engager molecule shows promise in r/r multiple myeloma
ASH 2020: Targeted therapies in r/r multiple myeloma
Peripheral blood CD26 leukaemia stem cell monitoring in CML during TKI treatment
Decitabine plus ipilimumab in r/r MDS/AML in the post-BMT or transplant naïve settings
Treating acute leukaemias of ambiguous lineage
Continuous therapy in multiple myeloma; updates from MM4 and MM6 including China perspective
First-in-class STAMP inhibitor asciminib in patients with CML harbouring the T315I mutation
Weekly carfilzomib, lenalidomide, dexamethasone and daratumumab (wKRd-D) combination therapy in newly diagnosed multiple myeloma
Analysis of the B-HOLISTIC study and importance of relapsed/refractory Hodgkin lymphoma real world evidence data
Five year update of ECHELON-1 for classical Hodgkin lymphoma
Off-the-shelf multi-virus specific T cells following haematopoietic stem cell transplantation
Blinatumomab and oral TKIs for the treatment of Ph ALL